Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid

Wonbeak Yoo, Donjeta Gjuka, Heather Stevenson-Lerner, Xiaoling Song, Hong Shen, Suk Young Yoo, Jing Wang, Michael Fallon, George N. Ioannou, Stephen A. Harrison, Laura Beretta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and ranges from isolated steatosis to NASH. To determine whether circulating fatty acids could serve as diagnostic markers of NAFLD severity and whether specific fatty acids could contribute to the pathogenesis of NASH, we analyzed two independent NAFLD patient cohorts and used the methionine- and choline-deficient diet (MCD) NASH mouse model. We identified six fatty acids that could serve as non-invasive markers of NASH in patients with NAFLD. Serum levels of 15:0, 17:0 and 16:1n7t negatively correlated with NAFLD activity scores and hepatocyte ballooning scores, while 18:1n7c serum levels strongly correlated with fibrosis stage and liver inflammation. Serum levels of 15:0 and 17:0 also negatively correlated with fasting glucose and AST, while 16:1n7c and 18:1n7c levels positively correlated with AST and ferritin, respectively. Inclusion of demographic and clinical parameters improved the performance of the fatty acid panels in detecting NASH in NAFLD patients. The panel [15:0, 16:1n7t, 18:1n7c, 22:5n3, age, ferritin and APRI] predicted intermediate or advanced fibrosis in NAFLD patients, with 82% sensitivity at 90% specificity [AUROC = 0.92]. 15:0 and 18:1n7c were further selected for functional studies in vivo. Mice treated with 15:0-supplemented MCD diet showed reduced AST levels and hepatic infiltration of ceroid-laden macrophages compared to MCD-treated mice, suggesting that 15:0 deficiency contributes to liver injury in NASH. In contrast, 18:1n7c-supplemented MCD diet didn’t affect liver pathology. In conclusion, 15:0 may serve as a promising biomarker or therapeutic target in NASH, opening avenues for the integration of diagnosis and treatment.

Original languageEnglish (US)
Article numbere0189965
JournalPLoS One
Volume12
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

fatty liver
Fatty Liver
Liver
Fatty Acids
fatty acids
choline
Diet
Choline
Nutrition
acids
Methionine
methionine
diet
liver
ferritin
Ferritins
fibrosis
Serum
Ceroid
mice

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Yoo, W., Gjuka, D., Stevenson-Lerner, H., Song, X., Shen, H., Yoo, S. Y., ... Beretta, L. (2017). Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. PLoS One, 12(12), [e0189965]. https://doi.org/10.1371/journal.pone.0189965

Fatty acids in non-alcoholic steatohepatitis : Focus on pentadecanoic acid. / Yoo, Wonbeak; Gjuka, Donjeta; Stevenson-Lerner, Heather; Song, Xiaoling; Shen, Hong; Yoo, Suk Young; Wang, Jing; Fallon, Michael; Ioannou, George N.; Harrison, Stephen A.; Beretta, Laura.

In: PLoS One, Vol. 12, No. 12, e0189965, 01.12.2017.

Research output: Contribution to journalArticle

Yoo, W, Gjuka, D, Stevenson-Lerner, H, Song, X, Shen, H, Yoo, SY, Wang, J, Fallon, M, Ioannou, GN, Harrison, SA & Beretta, L 2017, 'Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid', PLoS One, vol. 12, no. 12, e0189965. https://doi.org/10.1371/journal.pone.0189965
Yoo, Wonbeak ; Gjuka, Donjeta ; Stevenson-Lerner, Heather ; Song, Xiaoling ; Shen, Hong ; Yoo, Suk Young ; Wang, Jing ; Fallon, Michael ; Ioannou, George N. ; Harrison, Stephen A. ; Beretta, Laura. / Fatty acids in non-alcoholic steatohepatitis : Focus on pentadecanoic acid. In: PLoS One. 2017 ; Vol. 12, No. 12.
@article{6a58e348bf3b487fb9dba57cb2ab9362,
title = "Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and ranges from isolated steatosis to NASH. To determine whether circulating fatty acids could serve as diagnostic markers of NAFLD severity and whether specific fatty acids could contribute to the pathogenesis of NASH, we analyzed two independent NAFLD patient cohorts and used the methionine- and choline-deficient diet (MCD) NASH mouse model. We identified six fatty acids that could serve as non-invasive markers of NASH in patients with NAFLD. Serum levels of 15:0, 17:0 and 16:1n7t negatively correlated with NAFLD activity scores and hepatocyte ballooning scores, while 18:1n7c serum levels strongly correlated with fibrosis stage and liver inflammation. Serum levels of 15:0 and 17:0 also negatively correlated with fasting glucose and AST, while 16:1n7c and 18:1n7c levels positively correlated with AST and ferritin, respectively. Inclusion of demographic and clinical parameters improved the performance of the fatty acid panels in detecting NASH in NAFLD patients. The panel [15:0, 16:1n7t, 18:1n7c, 22:5n3, age, ferritin and APRI] predicted intermediate or advanced fibrosis in NAFLD patients, with 82{\%} sensitivity at 90{\%} specificity [AUROC = 0.92]. 15:0 and 18:1n7c were further selected for functional studies in vivo. Mice treated with 15:0-supplemented MCD diet showed reduced AST levels and hepatic infiltration of ceroid-laden macrophages compared to MCD-treated mice, suggesting that 15:0 deficiency contributes to liver injury in NASH. In contrast, 18:1n7c-supplemented MCD diet didn’t affect liver pathology. In conclusion, 15:0 may serve as a promising biomarker or therapeutic target in NASH, opening avenues for the integration of diagnosis and treatment.",
author = "Wonbeak Yoo and Donjeta Gjuka and Heather Stevenson-Lerner and Xiaoling Song and Hong Shen and Yoo, {Suk Young} and Jing Wang and Michael Fallon and Ioannou, {George N.} and Harrison, {Stephen A.} and Laura Beretta",
year = "2017",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0189965",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Fatty acids in non-alcoholic steatohepatitis

T2 - Focus on pentadecanoic acid

AU - Yoo, Wonbeak

AU - Gjuka, Donjeta

AU - Stevenson-Lerner, Heather

AU - Song, Xiaoling

AU - Shen, Hong

AU - Yoo, Suk Young

AU - Wang, Jing

AU - Fallon, Michael

AU - Ioannou, George N.

AU - Harrison, Stephen A.

AU - Beretta, Laura

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and ranges from isolated steatosis to NASH. To determine whether circulating fatty acids could serve as diagnostic markers of NAFLD severity and whether specific fatty acids could contribute to the pathogenesis of NASH, we analyzed two independent NAFLD patient cohorts and used the methionine- and choline-deficient diet (MCD) NASH mouse model. We identified six fatty acids that could serve as non-invasive markers of NASH in patients with NAFLD. Serum levels of 15:0, 17:0 and 16:1n7t negatively correlated with NAFLD activity scores and hepatocyte ballooning scores, while 18:1n7c serum levels strongly correlated with fibrosis stage and liver inflammation. Serum levels of 15:0 and 17:0 also negatively correlated with fasting glucose and AST, while 16:1n7c and 18:1n7c levels positively correlated with AST and ferritin, respectively. Inclusion of demographic and clinical parameters improved the performance of the fatty acid panels in detecting NASH in NAFLD patients. The panel [15:0, 16:1n7t, 18:1n7c, 22:5n3, age, ferritin and APRI] predicted intermediate or advanced fibrosis in NAFLD patients, with 82% sensitivity at 90% specificity [AUROC = 0.92]. 15:0 and 18:1n7c were further selected for functional studies in vivo. Mice treated with 15:0-supplemented MCD diet showed reduced AST levels and hepatic infiltration of ceroid-laden macrophages compared to MCD-treated mice, suggesting that 15:0 deficiency contributes to liver injury in NASH. In contrast, 18:1n7c-supplemented MCD diet didn’t affect liver pathology. In conclusion, 15:0 may serve as a promising biomarker or therapeutic target in NASH, opening avenues for the integration of diagnosis and treatment.

AB - Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and ranges from isolated steatosis to NASH. To determine whether circulating fatty acids could serve as diagnostic markers of NAFLD severity and whether specific fatty acids could contribute to the pathogenesis of NASH, we analyzed two independent NAFLD patient cohorts and used the methionine- and choline-deficient diet (MCD) NASH mouse model. We identified six fatty acids that could serve as non-invasive markers of NASH in patients with NAFLD. Serum levels of 15:0, 17:0 and 16:1n7t negatively correlated with NAFLD activity scores and hepatocyte ballooning scores, while 18:1n7c serum levels strongly correlated with fibrosis stage and liver inflammation. Serum levels of 15:0 and 17:0 also negatively correlated with fasting glucose and AST, while 16:1n7c and 18:1n7c levels positively correlated with AST and ferritin, respectively. Inclusion of demographic and clinical parameters improved the performance of the fatty acid panels in detecting NASH in NAFLD patients. The panel [15:0, 16:1n7t, 18:1n7c, 22:5n3, age, ferritin and APRI] predicted intermediate or advanced fibrosis in NAFLD patients, with 82% sensitivity at 90% specificity [AUROC = 0.92]. 15:0 and 18:1n7c were further selected for functional studies in vivo. Mice treated with 15:0-supplemented MCD diet showed reduced AST levels and hepatic infiltration of ceroid-laden macrophages compared to MCD-treated mice, suggesting that 15:0 deficiency contributes to liver injury in NASH. In contrast, 18:1n7c-supplemented MCD diet didn’t affect liver pathology. In conclusion, 15:0 may serve as a promising biomarker or therapeutic target in NASH, opening avenues for the integration of diagnosis and treatment.

UR - http://www.scopus.com/inward/record.url?scp=85038436271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038436271&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0189965

DO - 10.1371/journal.pone.0189965

M3 - Article

C2 - 29244873

AN - SCOPUS:85038436271

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0189965

ER -